1108-117 Reduced bone mass in men with advanced chronic heart failure is accompanied by hyperparathyroidism, andropenia, and inflammation, and predicts poor outcome  by Jankowska, Ewa A et al.
198A ABSTRACTS - Cardiac Function and Heart Failure JACC March 3, 2004
Ca
rd
ia
c 
Fu
nc
tio
n 
an
d 
He
ar
t F
ai
lu
re
was cardiac. Pts with atrial fibrillation (AF) and cardiac thrombus were more prone to
present an EE. The mean heart weight was 663.3 g, with no difference between those
with or without EE. There was no correlation also between LV diastolic diameter and
ejection fraction and EE.
Conclusions: EE were very frequent in pts with IDC, namely more than 50% of pts with
DCM that died at the hospital presented one or more EE. Our findings support the indica-
tion to anticoagulation for pts with AF and cardiac thrombi, but the degree of left ventricu-
lar dysfunction was not a good predictor of EE.
1108-113 Flow-Mediated Vasodilatation Predicts Outcome in 
Patients With Chronic Heart Failure
Brigitte Meyer, Martin Huelsmann, Karin Strecker, Thomas Neunteufl, Richard Pacher, 
Rudolf Berger, University Medical School of Vienna, Vienna, Austria
Background: Chronic heart failure (CHF) is associated with reduced endothelium-depen-
dent, flow mediated vasodilatation (FMD). The prognostic impact of this observation,
however, is unknown. The aim of the study was to assess the predictive potency of
impaired FMD in patients with CHF.
Methods: 75 CHF patients with a left ventricular ejection fraction (LVEF) < 30% despite
optimised medical therapy (angiotensin converting encyme inhibitor and angiotensin II
receptor blocker 100%, beta-blocker 81%) were evaluated. Using high resolution ultra-
sound, FMD of the brachial artery was assessed in addition to other neurohormonal, clin-
ical and hemodynamic variables. Age, gender, NYHA functional class, LVEF,
hemodynamic variables, natriuretic peptides, medical therapy, cardiovascular risk factors
and FMD were analysed for prediction of the combined endpoint death and HTx in a mul-
tivariate Cox model.
Results: Up to three years, 44 patients survived, 14 patients died and 17 patients under-
went urgent heart transplantation (HTx). Univariate risk factors for adverse outcome were
FMD (p=0.0044), log BNP (p=0.0063), log N-terminal ANP (p=0.0151), mean blood pres-
sure (p=0.0182), NYHA class (p=0.0216) and beta-blocker therapy (p=0.0429). In the
multivariate analysis, only FMD (p=0.0044) and log BNP (p=0.0030) were independently
related to adverse outcome. In the Kaplan-Meier blot, significantly more patients with a
FMD < 5.3% (median) reached the combined endpoint compared with patients with a
FMD > 5.3% (p=0,0007).
Conclusion: In CHF impaired FMD is a strong, independent predictor of adverse out-
come.
1108-114 The Relationship Between the VAS on the EQ-5D and 
the Kansas City Cardiomyopathy Questionnaire in 
Patients With Acute Myocardial Infarction Complicated 
by Heart Failure
Zefeng Zhang, John A. Spertus, Philip Jones, William S. Weintraub, Emory University 
School of Medicine, Atlanta, GA, Mid-America Heart Institute and the University of 
Missouri, Kansas, MO
Background: The EPHESUS trial was designed to evaluate the effect of eplerenone on
outcomes among patients with heart failure (HF) complicating acute myocardial infarction
(AMI). We sought to examine the relationship between utility and HF-related health sta-
tus in this patient population.
Methods: Utility was evaluated with visual analogue score (VAS) on the EQ-5D, an instru-
ment designed to measure patients’ preference values for a wide range of standardized
health states. Kansas City Cardiomyopathy Questionnaires (KCCQ), a 23-item health
status measure for HF, was used to evaluate HF-related quality of life. Questionnaires
were administered to 2280 patients at baseline, 1 month and 1 year.
Results: Scores for both utility and KCCQ overall summary score improved significantly
from baseline at 1 and 12 months (see Table). 
KCCQ overall summary score quartiles (<=42.3 (n=383), >42.3 to 62.5 (n=396), >62.5 to
82.3 (n=387), >=82.3 (n=383)) were significantly associated with EQ-5D scores
(46.4±19.0, 56.1±18.5, 63.5±18.2, 70.1±18.0; p<0.0001). Multivariate analysis adjusting
for age, gender and country indicated KCCQ scores to be the strongest independent pre-
dictor of the utility scores. Improvement in 1-year utility scores was significantly corre-
lated with improved 1-year KCCQ scores (r=0.45, p<0.0001).
Conclusions: While KCCQ is an important and independent predictor of utility scores in
patients with HF complicating AMI, it probably can not be used as proxy measure for util-
ity.
1108-115 Right Ventricular Function Recovery After Acute 
Myocardial Infarction: The Relation With Left Ventricular 
Function and Interventricular Septum Motion-The 
GISSI-3 Echo Substudy
Bogdan A. Popescu, Francesco Antonini-Canterin, Pantaleo Giannuzzi, Pier L. 
Temporelli, Enzo Bosimini, Francesco Gentile, Aldo P. Maggioni, Luigi Tavazzi, Rita 
Piazza, Luigi Ascione, Ioana Stoian, Eugenio Cervesato, Andreea C. Popescu, Gian L. 
Nicolosi, Centro Studi ANMCO, Firenze, Italy
Background. The pattern of right ventricular (RV) function recovery and its relation with
left ventricular (LV) function changes and interventricular septum (IVS) motion in low risk
patients after acute myocardial infarction (AMI) have not been assessed yet.
Methods. We studied a group of 500 patients (414 men, 60.8 ± 11.8 years) from the
GISSI-3 Echo Substudy, who survived 6 months after AMI and who underwent serial
echocardiograms at a mean of 36 ± 8 hours from symptom onset (S1), at hospital dis-
charge (mean 12 ± 5 days, S2), at 6 weeks (S3), and at 6 months (S4). The echocardio-
grams were analyzed in the Core Laboratory by experts blinded to all clinical data.
Tricuspid annular plane systolic excursion (TAPSE) was measured by 2-D echocardio-
graphy for RV systolic function assessment. The wall motion score index (WMSI) was
calculated for the whole LV (16 segments): global WMSI, for the IVS (5 segments): IVS-
WMSI, and for the LV free wall (11 segments). Changes in echocardiographic parame-
ters during follow-up (S4-S1), and the determinants of TAPSE at S1 and of TAPSE
changes were calculated.
Results. There was a significant increase in TAPSE during follow-up (from 1.79 ± 0.46 cm
at S1 to 1.92 ± 0.46 cm at S4, time effect: F=25, p<0.001), which was already significant
at S2 (1.88 ± 0.47 cm, time effect: F=26.7, p<0.001). LV ejection fraction (LVEF) was the
best correlate of TAPSE at S1 (r=0.15, p=0.001). Although at univariate analysis TAPSE
changes correlated with LVEF changes (r=0.12, p=0.008), with global WMSI changes (r=
- 0.11, p=0.013), and with IVS-WMSI changes (r= - 0.12, p=0.005), by multivariate analy-
sis IVS-WMSI changes emerged as the only independent predictor of TAPSE changes
during follow-up (r= - 0.12, p=0.007).
Conclusion. In low-risk patients after AMI, recovery in RV function occurs throughout 6-
month follow-up and is already significant at discharge. TAPSE is significantly related to
LVEF at S1. Changes in RV function during 6-month follow-up are related to global and
regional LV function changes, and best to IVS-WMSI improvement. This suggests that
IVS motion itself and IVS-mediated ventricular interaction are important mechanisms of
RV function improvement in this setting.
1108-116 Cardiac Power Output Is the Only Independent 
Hemodynamic Predictor of Outcome in Acute Heart 
Failure
Gad Cotter, Nir Uriel, Loic Perchenet, Edo kaluski, Isaac Kobrin, Aline Frey, Olga Milo, 
Alex Blatt, Shoshana Kaplan, Zvi Vered, Guillermo Torre-Amione, Assaf-Harofeh Medical 
Center, Zerifin, Israel, Methodist Hospital at Baylor College of Medicine, Houston, TX
In recent years the use of right heart catheterization for the stratification of patients with
acute heart failure has diminished, primarily since cardiac hemodynamics showed rather
poor correlation with outcome.
Methods: The purpose of the present study was to assess the predictive value of hemo-
dynamic variables at admission in conjunction with clinical variables in 120 patients
admitted with acute heart failure that underwent right heart catheterization at admission.
Patients were in the placebo arms of two multicenter international studies. We assessed
hemodynamic and clinical variables up to 30 days. In addition cardiac power output
(CPo) was calculated as CO *mean arterial blood pressure (MAP) and expressed in Watt
units.
Conclusion: Cardiac Power Output was the strongest hemodynamic predictor of recur-
rent heart failure events in patients admitted due to acute heart failure. Wedge pressure
had no correlation with recurrent events.
1108-117 Reduced Bone Mass in Men With Advanced Chronic 
Heart Failure Is Accompanied by Hyperparathyroidism, 
Andropenia, and Inflammation, and Predicts Poor 
Outcome
Ewa A. Jankowska, Agnieszka Kus, Justyna Jakubaszko, Jacek Majda, Waldemar 
Banasiak, Stefan Anker, Piotr Ponikowski, Military Hospital, Wroclaw, Poland, National 
Heart and Lung Institute, London, United Kingdom
Background Cardiac cachexia in patients (pts) with chronic heart failure (CHF) is
defined as deficiency of lean and fat tissues. Bone status as marker of cachexia in CHF
has not been studied.
Methods We examined bone mineral content (BMC) in arms, legs, trunk, total body
using dual energy X-ray absorptiometry in 123 consecutive male CHF pts (age: 59 ± 1 y,
LVEF: 31 ± 1 %, NYHA class I/II/III/IV: 10/61/40/12) and 37 men without CHF (age: 55 ±
1 y, LVEF: 59 ± 1 %). T-score (BMC compared to BMC of young adults, in standard devi-
ation units [SD]) and Z-score (BMC compared to BMC of age-matched healthy men, in
SD) were calculated.
Results CHF pts had reduced all BMC when compared to pts without CHF (all p<0.05).
CHF severity was related to reduction of all BMC (BMCtotal: 3.3 ± 0.1 / 3.0 ± 0.1 / 2.8 ±
0.1 / 2.5 ± 0.1 kg, NYHA I/II/III/IV, r = -0.23, p<0.01), T-score (0.5 ± 0.4 / -0.3 ± 0.1 / -0.4
Baseline 1 month 12 months p value
KCCQ scores 60.8 (n=1616) 68.8 (n=1516) 78.0 (n=1229) <0.001
EQ-5D scores 59.0 (n=1551) 66.4 (n=1470) 73.0 (n=1216) <0.001
7 Days Recurrent 
WHF
30 Days 
Recurrent WHF
Variables RR (95% CI) P Value RR (95% CI) P Value
Age 1.3 (0.65-2.7) 0.44 1.3 (0.68-2.5) 0.42
Body Mass Index 0.79 (0.41-1.5) 0.47 0.72 (0.4-1.3) 0.3
Creatinine 0.76 (0.39-1.46) 0.41 0.64 (0.35-1.12) 0.15
Cardiac Index 0.73 (0.39-1.46) 0.41 0.74(0.39-1.4) 0.32
Cardiac Output 0.68 (0.34-1.35) 0.27 0.7 (0.37-1.3) 0.26
Cardiac Power Output 0.47 (0.24-0.93) 0.0029 # 0.55 (0.3-1.03) 0.06
Wedge Pressure 1.4 (0.69-3) 0.33 1.44 (0.7-2.6) 0.36
Peripheral Vascular 
resistance
1.55 (0.78-3.1) 0.21 1.4 (0.7-2.6) 0.36
Mean Arterial Blood 
Pressure
0.6 (0.3-1.2) 0.15 0.6 (0.3-1.2) 0.15
Sex (Female) 0.63 (0.32-1.24) 0.18 0.66 (0.35-1.2) 0.19
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± 0.2 / -1.4 ± 0.4 SD, r = -0.24, p<0.01), Z-score (0.7 ± 0.5 / -0.2 ± 0.1 / -0.3 ± 0.2 / -0.9 ±
0.3 SD, r = -0.22, p<0.01). Osteopenia (T-score < -1.0) was found in 20% and 29% pts in
NYHA I-II and III-IV, respectively, and osteoporosis (T-score < -2.5) in 9% pts in NYHA III-
IV. There were no osteopenia or osteoporosis in controls. CHF pts with osteopenia or
osteoporosis compared to pts with normal BMC had reduced peak VO2 (13.9±0.9 vs
16.5±0.8 mL/kg/min), decreased fat and lean mass (17±1 vs 23±1 kg, 52±1 vs 57±1 kg,
respectively), increased C-reactive protein level (48±37 vs 13±5 mg/L), increased par-
athormone level (113±18 vs 73±10 pg/mL), reduced levels of dehydroepiandrosterone
sulphate, total, free and bioavailable testosterone (54±10 vs 97±15 µg/dL, 3.0±0.6 vs
4.5±0.3 ng/mL, 9±2 vs 16±2 ng/dL, 212±49 vs 367±36 ng/dL, respectively) (all p<0.05).
During the 18-month follow-up, 18 (15 %) pts died. Reduced bone mass (BMC-total < vs
> 3 kg) was related to poor survival in univariate analysis (RR=3.7, 95%CI - 1.2-11.3,
p<0.05), not when adjusted for NYHA class, peak VO2.
Conclusions. Bone loss accompanied by reduced fat and lean mass is observed in CHF
pts, in particular in advanced stages, and is related to poor outcome. Hyperparathyroid-
ism, adrenal and gonadal andropenia, inflammation may be important in the pathogene-
sis of bone loss in CHF, but further studies are needed.
1108-118 Comparative Yield of Clinical, Laboratory, 
Echocardiographic, and Neurohormonal Predictors of 
Outcome in Heart Failure Patients (Val-HeFT Data)
Lidia Staszewsky, Maylene Wong, Simona Barlera, Elisa Carretta, Serge Masson, 
Roberto Latini, Aldo P. Maggioni, Jay N. Cohn, Gianni Tognoni, Istituto di Ricerche 
Farmacologiche, Milan, Italy, VA Greater Los Angeles Healthcare System, Los Angeles, 
CA
Introduction: Numerous variables are prognostic of HF, but not all are widely available.
Val-HeFT data which contain a full complement of bedside, laboratory, echocardio-
graphic, and neurohormonal endpoints were analyzed for comparative predictive value.
Methods: Pooled baseline data from the history (H), physical examination (PE), and labo-
ratory from Val-HeFT included age, sex, etiology, NYHA class, symptoms, signs, labora-
tory, EF and LVIDd. Except for age, continuous variables were considered above and
below the median. Adjusted RR for mortality at study endpoint and 95% CI from a multi-
variate Cox analysis with stepwise selection are presented. Results: Patients with all data
available (N=4284) were predominantly white, aged 63 y, males/ females=4/1, 98%
NYHA class II & III, 57% ischemic etiology, EF=26.8±7.2% (mean±SD),
LVIDd=6.9±0.9cm. 828 patients died over 23 months follow-up. BNP, LVIDd, NE and cre-
atinine were the strongest independent predictors of mortality. The other significant pre-
dictors were variables from the H & PE. Leg, thigh or sacral edema showed a high RR
but a low prevalence; high grade of dyspnea on effort increased the RR > 30% (table).
NYHA class and EF were not statistically significant. Conclusions: Independent markers
of mortality were findings from the H & PE, review of systems, laboratory, and M-mode
echocardiography. Therefore, conventional bedside evaluation with a limited set of labo-
ratory data can provide a powerful aggregate for predicting mortality.
1108-119 Clinical Outcome in Patients With Preoperative 
Congestive Heart Failure Undergoing Coronary Artery 
Bypass Graft Surgery
Mohan Babapulle, Kristian B. Filion, Seema Haider, Louise Pilote, Mark J. Eisenberg, 
Jewish General Hospital, Montreal, PQ, Canada
Background: Coronary artery bypass graft surgery (CABG) is frequently performed in
patients with chronic congestive heart failure (CHF). However, there have been no large-
scale studies specifically examining clinical outcome in patients with pre-operative CHF
undergoing CABG.
Methods: We extracted data from the resource and cost accounting systems of 5 U.S
and 4 Canadian hospitals on 12,017 consecutive patients undergoing CABG between
1997-2001. Of these patients 1,176 (9.8%) had pre-operative CHF, and 10,841 (90.2%)
did not. We examined the post-operative length of stay (LOS) and in-hospital mortality in
patients with and without CHF. We performed a log transformation of LOS data, and iden-
tified independent predictors of LOS using a multiple linear regression model. We
adjusted for covariates of mortality using multivariate logistic regression.
Results: Patients with pre-operative CHF were older (69.9 ± 9.8 years vs. 64.9 ± 10.2
years), and were more likely to be female (65.0% vs. 77.2%), to have diabetes (36.9% vs.
24.9%) and to have cerebrovascular disease (10.2% vs. 5.1%). The CHF group was also
more likely to undergo non-elective CABG (69.9% vs. 55.2%) and reoperation (8.9% vs.
5.6%). Compared to patients without CHF, patients with CHF had a longer unadjusted
post-operative LOS (11.0 ± 0.5 days vs. 6.8 ± 0.07 days). After adjusting for clinical differ-
ences, the LOS in CHF patients was 38% longer than those without CHF (95% Confi-
dence Interval (CI) 33-43%, P<0.0001). Patients with CHF also had a higher unadjusted
in-hospital mortality rate compared to patients without CHF (6.0% vs. 1.3%). The
adjusted odds ratio for mortality was 3.52 (95% CI 2.36-5.25, P<0.0001).
Conclusions: Compared to patients without pre-operative CHF, patients with pre-opera-
tive CHF have a longer post-operative LOS, and a more than 3-fold higher in-hospital
mortality rate following CABG.
1108-120 A Gap in Care: Heart Failure Patients Undergoing Major 
Noncardiac Surgery
Adrian F. Hernandez, David J. Whellan, Sharon Stroud, Jie Lena Sun, Christopher M. 
O'Connor, James G. Jollis, Duke Clinical Research Institute, Durham, NC
Background:Perioperative care has reduced the complications in patients with coronary
artery disease (CAD) undergoing major noncardiac surgery but outcomes of heart failure
(HF) patients are unknown.
Methods: Using the 1997-98 Standard Analytic File 5% Sample of Medicare beneficia-
ries, we identified pts with an index HF admission. From this cohort, we identified pts with
a subsequent major noncardiac surgery within one year of the index HF hospitalization.
We used a multivariable logistic regression model to provide adjusted mortality and read-
mission rates in pts after noncardiac surgery. Patients hospitalized with CAD and later
had a major noncardiac surgery as well as the remaining pts (Control) who had similar
surgery served as reference groups.
Results: There were 23,340 HF pts and 28,710 CAD pts who were hospitalized and sur-
vived to discharge. In the next year, there were 1,532 HF pts (6.56%) and 1,757 (6.12%)
CAD pts who underwent surgery. There were 44,512 pts in the Control group. After
accounting for demographics and comorbid conditions, the risk adjusted inpatient and
30-day mortality in discharged pts was HF-15.8%, CAD- 8.0% and Control-7.3%
(p<0.001). The risk-adjusted 30-day readmission rate was HF- 21.0%, CAD-14.3% and
Control-11.0% (p<0.001).
Conclusion: HF patients undergoing major noncardiac surgery suffer significant morbidity
and mortality despite advances in perioperative care while patients with CAD have simi-
lar mortality compared to a more general population.
1108-121 Survival Benefit With Spironolactone Therapy Is Not 
Related to Reduced hsCRP Levels in Severe Congestive 
Heart Failure: Results From a RALES Substudy
Michel F. Rousseau, Annie R. Robert, Ronald Van Beneden, Virginie de Coninck, Sylvie 
A. Ahn, Jean-Marie Ketelslegers, Hubert G. Pouleur, University of Louvain, Brussels, 
Belgium
In the RALES study, Spironolactone (Spiro), an aldosterone receptor antagonist,
decreased mortality and morbidity in patients with severe congestive heart failure. To
clarify the mechanism of action, particularly the role of inflammation on progression of
heart failure and cardiovascular events, the effects of Spiro (25 mg/daily) on plasma con-
centrations of high sensitivity C-reactive protein (hsCRP) were assessed in a subset of
113 patients (NYHA III-IV, mean EF : 25%) at entry (T0) into study, at 3 months (T3) and
at 6 months (T6) and compared the changes to the Placebo group. 54 patients were
included in the Spiro group and 59 in the Placebo group. Results were expressed in mg/
dL, geometric mean [95% CI] and data were compared using a Student t-test on a
logtransformed scale. The hsCRP changes from baseline are expressed by the ratios T3/
T0 and T6/T0 (see table).
At baseline, hsCRP levels were elevated with no significant differences between groups.
During follow-up, similar hsCRP reductions from baseline were observed in Placebo and
Spiro groups reaching statistical significance at T6 (-40%, p=0.02 and -41%, p=0.02,
respectively), with values close to normal. None of the between groups comparisons
reached statistical significance.
Thus, in this small cohort of patients with severe congestive heart failure, there was no
Covariate Frequency(%) RR [95%CI] Chi-
Square 
p_value
BNP>97 pg/mL 50 1.85 [ 1.56 - 2.15] 61 <.0001
LVIDd>6.8 cm 54 1.49 [1.23 - 1.72] 28 <.0001
Norepinephrine>394 pg/
mL
50 1.39 [1.21 - 1.61] 20 <.0001
Creatinine>107 µmol/L 51 1.40 [1.21 - 1.61] 20 <.0001
Edema leg/thigh/sacrum 2 2.01 [1.45 - 2.77] 18 <.0001
Digoxin prescribed 67 1.40 [1.19 - 1.65] 16 <.0001
Age>70y 29 1.33 [1.14 - 1.54] 14 0.0002
Ischemic Etiology 57 1.32 [1.14 - 1.54] 14 0.0002
Dyspnea on effort 3+/4+ 33 1.30 [1.12 - 1.50] 12 0.0004
BB not prescribed 65 1.31 [1.12 - 1.54] 12 0.0006
Paroxysmal nocturnal 
dyspnea
9 1.40 [1.14 - 1.72] 10 0.0014
Systolic BP<121 mmHg 49 1.23 [1.07 - 1.42] 9 0.0032
BMI >22 kg/m2 10 1.32 [1.08 - 1.60] 8 0.0055
